A Phase 2 interventional study of pemetrexed and cisplatin in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Terminated at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-02.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 195th largest by enrollment of the 224 interventional ones that give a count, is one of 20 that started in 2005, is one of 128 in phase 2, and was the 24th registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 48 · Phase 4 8
First in 2001; this study’s year is marked. 20 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 224 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 228 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 134th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2005, is one of 73 in phase 2, and was the 34th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
To determine the response to this regimen for therapy prior surgery in patients with locally advanced disease or metastatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: cisplatin
500 mg/m2, intravenous (IV), every 21 days x 3 cycles
Also known as: LY231514, Alimta
75 mg/m2, intravenous (IV), every 21 days x 3 cycles
Treatment Response
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
Time frame: every 21 day cycle (3 cycles) and 3-4 weeks after last cycle
Pathologic Remissions After Surgery
The status of the pathological response was evaluated on the basis of the original results of the histopathological examination of the tumour samples resected. A complete pathological response was defined as the absence of any viable tumour cell in the tumour samples obtained for histological examination.
Time frame: surgical tumor resection (3-4 weeks after completing three 21-day cycles of therapy)
Relapse-free Survival
Results for this outcome measure were not analyzed because the trial stopped early due to low enrollment.
Time frame: Every 21 day cycle (3 cycles) and then every 3 months for the first 2 years, every 6 months until 5 years have elapsed and annually thereafter
| Milestone | Pemetrexed + Cisplatin |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.
| participants | Pemetrexed + Cisplatin |
|---|---|
| Complete Response | 0 |
| Partial Response | 5 |
| Incomplete Response/Stable Disease | 4 |
| Progressive Disease | 1 |
| Not Evaluable | 0 |
The status of the pathological response was evaluated on the basis of the original results of the histopathological examination of the tumour samples resected. A complete pathological response was defined as the absence of any viable tumour cell in the tumour samples obtained for histological examination.
| participants | Pemetrexed + Cisplatin |
|---|---|
| Complete Remission - Yes | 5 |
| Complete Remission - No | 2 |
Results for this outcome measure were not analyzed because the trial stopped early due to low enrollment.
No measurements were reported for this outcome.
Non-serious events are listed at a 10% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | — | — |
| Event | Pemetrexed + Cisplatin |
|---|---|
| Urinary tract infectionInfections and infestations | 1/10 |
| Event | Pemetrexed + Cisplatin |
|---|---|
| NauseaGastrointestinal disorders | 4/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/10 |
| VomitingGastrointestinal disorders | 2/10 |
| Alanine aminotransferase increasedInvestigations | 2/10 |
| Aspartate aminotransferase increasedInvestigations | 2/10 |
| RashSkin and subcutaneous tissue disorders | 2/10 |
| LeukocytosisBlood and lymphatic system disorders | 1/10 |
| LeukopeniaBlood and lymphatic system disorders | 1/10 |
| NeutrophiliaBlood and lymphatic system disorders | 1/10 |
| Abdominal DistensionGastrointestinal disorders | 1/10 |
| Age Continuous(years) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 61.6 ± 8.2 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin |
|---|---|
| Female | 4 |
| Male | 6 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin |
|---|---|
| Spain | 10 |
| Eastern Cooperative Oncology Group Functional Status(participants) | Pemetrexed + Cisplatin |
|---|---|
| 0 - Fully Active | 8 |
| 1 - Ambulatory, Restricted Strenuous Activity | 2 |
| 2 - Ambulatory, No Work Activities | 0 |
| 3 - Partially Confined to Bed, Limited Self Care | 0 |
| 4 - Completely Disabled | 0 |
| Race/Ethnicity(participants) | Pemetrexed + Cisplatin |
|---|---|
| Caucasian | 10 |
| Body Mass Index(kilograms per square meters) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 27.1 ± 4.3 |
| Corporal Surface (Body Surface Area)(square meters) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 1.8 ± 0.2 |
| Height(meters) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 1.6 ± 0.1 |
1 further baseline measures are reported on the registry.
The record gives a start of Nov 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin
Carcinoma, Non-Small-Cell Lung →